Age: 64.0
Sex: F
Vaccine: FLUX, PPV, FLUX, PPV, FLU3, PPV
Symptoms: Asthma, Cough, Dyspnoea, Respiratory distress
Clinical narrative: This spontaneous report as received from a 65 year old diabetic female consumer with high blood pressure, irritable bowel syndrome, drug reaction/allergy to morphine and DARVOCET-N refers to herself. On 10-NOV-2013 the patient received unspecified flu vaccine (manufacturer unknown) (lot#, dose and route unknown) and pneumococcal vaccine (manufacturer unknown) (lot #, dose and route unknown). On 17-NOV-2013, reported as the following Sunday, she experienced a severe cough with respiratory distress which caused her difficulty breathing and eventually she was hospitalized (hospital unspecified) over Christmas time (unspecified date) for 3 days. Consumer stated that she used a nebulizer with an unspecified medication to help treat her condition while in the hospital. Consumer stated that after she was discharged from the hospital, she was seen by another physician at the same facility. Consumer noted that the physician stated that her lungs indicated that she had a severe asthma attack. Outcome of adverse event was not reported at the time of the report. Follow up information was received from physician. On 14-FEB-2014, a phone call was placed to the physician and the receptionist due to physician's absence transferred call to employee of medical records department. She reported that the patient was hospitalized on 23-DEC-2013 and faxed a copy of the medical records. The reporter stated via medical record that the patient also had drug allergies to adhesive tape, ALTACE, LORCET. Reporter stated that the patient experienced on an unspecified date chronic obstructive pulmonary disease (COPD) exacerbation (exac) and was in poor condition (cond) and was hospitalized on 23-DEC-2013 for observation services. The patient was performing activity as needed (PRN) and was placed on 1800 calorie diabetic diet. The patient was scheduled complete blood count (CBC), chem 12 and glycosylated hemoglobin (HgbA1c), electrocardiogram (EKG), chest X-ray (cXr) posterior-anterior and lateral (PA + LAT), sputum for culture and admission blood glucose (ABG) tests (results not provided). The patient was treated with intravenously (IV) normal saline to keep vein open (NS at KVO), four time a day (QID) nebulization with ATROVENT 0.2 (unit not provided), albuterol (manufacturer unknown) 0.083 (unit not provided), QVAR 80 (unit not provided) two times a day (BID) with albuterol (manufacturer unknown) and SOLU-MEDROL 80 mg IV every 8 hours (Q8H). On 24-DEC-2013, the patient was discharged from hospital and instruction to continue taking medications from home. Discharge of diagnosis: chronic obstructive pulmonary disease (COPD) exacerbation (exac) and diabetes mellitus type I. The patient was prescribed ROCEPHIN 1 gram, IV daily; ZITHROMAX 500 mg, IV daily; TESSALON 100 mg orally (PO), QID; PHENERGAN with codeine PO every 4 hours (Q4H or as needed (PRN) for cough. The patient was also scheduled CBC and Chem 12. It was noted that contact with patient's physician should be made. Outcome of COPD exacerbation was not reported at the time of the report. The relatedness between adverse events and pneumococcal vaccine (manufacturer unknown) and unspecified flu vaccine (manufacturer unknown) was unknown. Treatment and instructions: patient stable, chest clear, "hearth AAA" and abdominal soft (date unspecified). Medicines prescribed reported as "7 path (pioglitazone hydrochloride)", "curtin" 500 and MEDROL. All available medical records will be provided upon request. Upon internal review Aortic aneurysm was considered medically significant. Follow up information has been received. On 23-DEC-2013, the patient was hospitalized. It was reported that a copy of the hospital records would be faxed and a copy of the lot numbers and expiration dates of AFLURIA and PNEUMOVAX would also be faxed if they are available. No further information at this time. Follow up information has been received from physician who refers to a 65 years old, female patient (patient's height was reported as 182 - units not provided) with current conditions included sickness, weakness and congestion. The patient did not experienced any adverse events following prior vaccination. On 08-NOV-2013 the patient was vaccinated with a dose (number reported as multiple) FLUZONE (lot # UH899AD) and with 5th or 6th dose of PNEUMOVAX23 (lot # J007059, exp. 31-JUL-2014). On unknown date patient experienced weakness, cough, malaise, dyspnea and arthralgia and was hospitalized for 3 days. Outcome of weakness, malaise, and arthralgia was unknown. Relatedness between weakness, malaise, arthralgia and FLUZONE, PNEUMOVAX23 was unknown. Events of weakness, cough, malaise, dyspnea and arthralgia was considered to be disabling by the reporter. Additional information is not expected. This report is linked to same patient report MARRS 1401USA013330.